Evidence map›Paper›PMID 38323831›Full record

ArticlemBio2024

Oxidative stress changes the effectiveness of artemisinin in

Camilla Valente Pires, Debora Cassandra, Shulin Xu, Benoit Laleu, Jeremy N Burrows, John H Adams

Open access · goldAbstract read
In one paragraph

Article in mBio, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Camilla Valente PiresCenter for Global Health and Interdisciplinary Diseases Research and USF Genomics Program, College of Public Health, University of South Florida, Tampa, Florida, USA.ORCID 0000-0002-5470-1342
Debora CassandraCenter for Global Health and Interdisciplinary Diseases Research and USF Genomics Program, College of Public Health, University of South Florida, Tampa, Florida, USA.
Shulin XuCenter for Global Health and Interdisciplinary Diseases Research and USF Genomics Program, College of Public Health, University of South Florida, Tampa, Florida, USA.
Benoit LaleuMedicines for Malaria Venture, ICC, Geneva, Switzerland.
Jeremy N BurrowsMedicines for Malaria Venture, ICC, Geneva, Switzerland.
John H AdamsCenter for Global Health and Interdisciplinary Diseases Research and USF Genomics Program, College of Public Health, University of South Florida, Tampa, Florida, USA.ORCID 0000-0003-3707-7979
University of South Florida · USMedicines for Malaria Venture · CH

Funding

Chemogenomic Profiling of Plasmodium Falciparum Responses and ResistanceR01AI117017 · NIAID · UNIVERSITY OF SOUTH FLORIDA · PI ADAMS, JOHN H · 2015 to 2025
$6.9M
Discovering the essential genome of Plasmodium falciparumR01AI130171 · NIAID · UNIVERSITY OF SOUTH FLORIDA · PI ADAMS, JOHN H · 2018 to 2021
$2.8M
NIAID NIH HHS R01 AI117017NIAID NIH HHS R01 AI130171
6 · The paper itself

Abstract

Malaria parasites have adaptive mechanisms to modulate their intracellular redox status to tolerate the enhanced oxidizing effects created by malaria fever, hemoglobinopathies and other stress conditions, including antimalaria drugs. Emerging artemisinin (ART) resistance in IMPORTANCE: Emerging resistance to the frontline antimalarial drug artemisinin represents a significant threat to worldwide malaria control and elimination. The patterns of parasite changes associated with emerging resistance represent a complex array of metabolic processes evident in various genetic mutations and altered transcription profiles. Genetic factors identified in regulating

Indexed as

Anemia, Sickle CellAntimalarialsArtemisininsFolic Acid AntagonistsHemoglobinopathiesMalariaMalaria, FalciparumDrug CombinationsDrug ResistanceHumansLumefantrineOxidative StressPlasmodium falciparumProtozoan ProteinsAntimalarialsartemisininArtemisininsDrug CombinationsFolic Acid AntagonistsLumefantrineProtozoan Proteinsantimalarial agentsartemisindrug resistance evolutionmalariaoxidative stress

Identifiers

PMID38323831
PMCPMC10936410
OpenAlexW4391600435

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.